Gefitinib Sensitivity-related Gene Expression And Products And Methods Related Thereto

Abstract

Disclosed is the identification, provision and use of a panel of biomarkers that predict sensitivity or resistance to gefitinib and other EGFR inhibitors, and products and processes related thereto. Specifically, a method is described for selecting a cancer patient who is predicted to benefit from therapeutic administration of an EGFR inhibitor, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitor. Also described is a method to identify molecules that interact with the EGFR pathway to allow or enhance responsiveness to EGFR inhibitors, as well as a plurality of polynucleotides or antibodies for the detection of the expression of genes that are indicative of sensitivity or resistance to EGFR inhibitors, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitors. A method to identify a compound with the potential to enhance the efficacy of EGFR inhibitors is also described.


Claims
Download PDF
Document Preview
Document History
  • Publication: Sep 13, 2011
  • Application: Jan 24, 2005
    US US 58705205 A
  • Priority: Jan 24, 2005
    US US 58705205 A
  • Priority: Jan 24, 2005
    US US 2005/0002325 W
  • Priority: Jan 23, 2004
    US US 53868204 P

Download Citation


Sign in to the Lens

Feedback